Literature DB >> 3921623

Development of bactericidal antibody during Branhamella catarrhalis infection.

A J Chapman, D M Musher, S Jonsson, J E Clarridge, R J Wallace.   

Abstract

The recent observation that Branhamella catarrhalis may cause a variety of infections in humans has stimulated interest in human host defenses against this organism. We encountered 21 patients with B. catarrhalis infection: seven with pneumonia, 13 with a purulent exacerbation of chronic bronchitis, and one with purulent sinusitis. Normal human serum (NHS) demonstrated no bactericidal activity against 20 of the 21 isolates. In contrast, 7 of 19 acute and 18 of 20 convalescent sera demonstrated significant bactericidal effects against the corresponding B. catarrhalis isolate. Heating convalescent sera to 56 C for 30 min abolished bactericidal activity. This activity was restored by NHS but not by complement-rich guinea pig serum. Selective blockage of the classic complement pathway eliminated bactericidal activity, whereas selective blockage of the alternative pathway did not. IgG isolated from convalescent serum plus NHS was bactericidal for the corresponding B. catarrhalis isolate. These results suggest that most patients with pulmonary infections due to B. catarrhalis develop a convalescent IgG antibody response that mediates serum bactericidal activity by the classic complement pathway.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3921623     DOI: 10.1093/infdis/151.5.878

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  40 in total

1.  Labile type-specific antigen of Moraxella catarrhalis.

Authors:  S J Norkus; J W Vennes
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

Review 2.  Moraxella catarrhalis bacteremic pneumonia in adults: two cases and review of the literature.

Authors:  J Collazos; J de Miguel; R Ayarza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

Review 3.  Lung infections. 2. Branhamella catarrhalis: epidemiological and clinical aspects of a human respiratory tract pathogen.

Authors:  T F Murphy
Journal:  Thorax       Date:  1998-02       Impact factor: 9.139

4.  Serum antibody response to outer membrane proteins of Moraxella (Branhamella) catarrhalis in patients with bronchopulmonary infection.

Authors:  J J Christensen; N Q Hansen; B Bruun
Journal:  Clin Diagn Lab Immunol       Date:  1996-11

Review 5.  [Moraxella catarrhalis: virulence and resistance mechanisms].

Authors:  W Cullmann
Journal:  Med Klin (Munich)       Date:  1997-03-15

6.  A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model.

Authors:  M E Helminen; I Maciver; J L Latimer; L D Cope; G H McCracken; E J Hansen
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

Review 7.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

8.  Differences in complement activation between complement-resistant and complement-sensitive Moraxella (Branhamella) catarrhalis strains occur at the level of membrane attack complex formation.

Authors:  C M Verduin; M Jansze; C Hol; T E Mollnes; J Verhoef; H van Dijk
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

9.  Serological identification of Branhamella catarrhalis. Serological evidence for infection.

Authors:  I Eliasson
Journal:  Drugs       Date:  1986       Impact factor: 9.546

10.  Human immune response against outer membrane proteins of Moraxella (Branhamella) catarrhalis determined by immunoblotting and enzyme immunoassay.

Authors:  M E Helminen; R Beach; I Maciver; G Jarosik; E J Hansen; M Leinonen
Journal:  Clin Diagn Lab Immunol       Date:  1995-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.